


58049-00032
PATENT
1AP20 Rec'd PTO 26 JUN 2006

I hereby certify that on June 26, 2006, which is the date I am signing this certificate, I am depositing this correspondence and all identified attachments with the U.S. Postal Service, postage prepaid, in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Joseph Hyosuk Kim

Applicant: **LEE, Kyu Hyun et al.**
Serial No.: N/A
Filed: **June 26, 2006**
Confirmation No.: N/A
Title: **"THERAPEUTIC AGENT FOR TREATMENT OF CANCER COMPRISING HUMAN APOLIPOPROTEIN (A) KRINGLES LK68 OR LK8 GENES AS EFFECTIVE INGREDIENT, AND METHOD FOR TREATING CANCER USING THE SAME"**
Examiner: N/A
Art Unit: N/A
Attorney Docket No.: **58049-00032**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

English Language Non-patent Documents:

SCHULTER et al., "IMPACT OF APOLIPOPROTEIN(a) ON IN VITRO ANGIOGENESIS,"
--

ARTERIOSCLER THROMB VASC BIOL. 21:433-438 (2001)
ASSMANN et al., "HYPERTRIGLYCERIDEMIA AND ELEVATED LIPOPROTEIN(a) ARE RISK FACTORS FOR MAJOR CORONARY EVENTS IN MIDDLE-AGED MEN," Am J Cardiol 77:1179-1184 (1996)
FLESS et al., "PHYSICOCHEMICAL PROPERTIES OF APOLIPOPROTEIN(a) AND LIPOPROTEIN(a-) DERIVED FROM THE DISSOCIATION OF HUMAN PLASMA LIPOPROTEIN (a)," Journal of Biological Chemistry 261(19):8712-8718 (1986)
ARMSTRONG et al., "THE ASSOCIATION BETWEEN SERUM Lp(a) CONCENTRATIONS AND ANGIOGRAPHICALLY ASSESSED CORONARY ATHEROSCLEROSIS," Atherosclerosis 62:249-257 (1986)
LEE et al., "ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF APOLIPOPROTEIN (a) KRINGLES SUPPRESSES HEPATOCELLULAR CARCINOMA GROWTH IN MICE," Hepatology 43:1063-1073 (2006)
TRIEU and UCKUN, "APOLIPOPROTEIN(a), A LINK BETWEEN ATHEROSCLEROSIS AND TUMOR ANGIOGENESIS," Biochemical and Biophysical Research Communications 257:714-718 (1999)

Foreign Language Document:

KR 10-2003-0010797 Aug. 27, 2004


It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

This Information Disclosure Statement is being filed within three (3) months of the filing date of the above-identified application and before the mailing date of a first Office Action on the merits in the above-identified case. Therefore, it is believed that no fee is required in connection with the filing of this Information Disclosure Statement.

However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge JHK Law's Deposit Account No. **502486** for such fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

June 26, 2006
Date



Joseph Hyosuk Kim, Ph.D.
Reg. No. 41,425
Attorney for Applicants

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: (818) 249-8177
Facsimile: (818) 249-8277

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 1 of 1	Application Number	N/A
	Filing Date	Herewith
	First Named Inventor	LEE, Kyu Hyun
	Art Unit	N/A
	Examiner Name	N/A
	Attorney Docket Number	58049-00032

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	SCHULTER et al., "IMPACT OF APOLIPOPROTEIN(a) ON IN VITRO ANGIOGENESIS," ARTERIOSCLER THROMB VASC BIOL. 21:433-438 (2001)	
	C2	ASSMANN et al., "HYPERTRIGLYCERIDEMIA AND ELEVATED LIPOPROTEIN(a) ARE RISK FACTORS FOR MAJOR CORONARY EVENTS IN MIDDLE-AGED MEN," Am J Cardiol 77:1179-1184 (1996)	
	C3	FLESS et al., "PHYSICOCHEMICAL PROPERTIES OF APOLIPOPROTEIN(a) AND LIPOPROTEIN(a-) DERIVED FROM THE DISSOCIATION OF HUMAN PLASMA LIPOPROTEIN (a)," Journal of Biological Chemistry 261(19):8712-8718 (1986)	
	C4	ARMSTRONG et al., "THE ASSOCIATION BETWEEN SERUM Lp(a) CONCENTRATIONS AND ANGIOGRAPHICALLY ASSESSED CORONARY ATHEROSCLEROSIS," Atherosclerosis 62:249-257 (1986)	
	C5	LEE et al., "ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF APOLIPOPROTEIN (a) KRINGLES SUPPRESSES HEPATOCELLULAR CARCINOMA GROWTH IN MICE," Hepatology 43:1063-1073 (2006)	
	C6	TRIEU and UCKUN, "APOLIPOPROTEIN(a), A LINK BETWEEN ATHEROSCLEROSIS AND TUMOR ANGIOGENESIS," Biochemical and Biophysical Research Communications 257:714-718 (1999)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	N/A
Filing Date	Herewith
First Named Inventor	LEE, Kyu Hyun
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	58049-00032

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	B1	KR 10-2003-0010797	08-27-2004	YOO et al	Whole Document	<input checked="" type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.